A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)

Beijing Chest Hospital0 sites60 target enrollmentJuly 7, 2021

ConditionsNon-small Cell Lung Cancer

InterventionsCarrelizumab + chemotherapy + apatinib

DrugsCarrelizumab + chemotherapy + apatinib

Overview

Phase: Not Applicable
Intervention: Carrelizumab + chemotherapy + apatinib
Conditions: Non-small Cell Lung Cancer
Sponsor: Beijing Chest Hospital
Enrollment: 60
Primary Endpoint: Progression-free survival
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with chemotherapy in the first-line treatment of advanced in NSCLC patients.

Registry

clinicaltrials.gov

Start Date

July 7, 2021

End Date

April 4, 2024

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Beijing Chest Hospital

Responsible Party

Principal Investigator

Ying Hu

Vice Director, Department of oncology

Beijing Chest Hospital

Eligibility Criteria

Inclusion Criteria

•The subjects were 18-70 years old when they signed the informed consent form, and the age was unlimited for men and women;
•The late stage (Ⅲ b/ Ⅲ C) and stage IV non-small cell lung cancer (according to AICC Eighth Edition) which can not be removed by operation and can not be treated with radical radiotherapy and chemotherapy confirmed by histopathology or cytology;
•EGFR mutation and alk translocation status were confirmed to be negative at any time after the initial diagnosis;
•Subjects had not received systemic systemic chemotherapy for advanced / metastatic NSCLC. Chemotherapy and / or radiotherapy are allowed to be used as part of new adjuvant / adjuvant treatment, provided that the treatment has been completed for at least six months before the diagnosis of advanced or metastatic diseases;
•ECoG score; 0-1 point;
•According to RECIST v1.1, subjects must have measurable target lesions through CT or MRI examination. The imaging assessment of tumor was performed within 28 days before the first drug use;
•The main organs function normally, and the test results during screening must meet the following requirements:
•The blood routine examination standard should meet the requirements (no blood transfusion and blood products within 14 days, no correction by G-CSF and other hematopoietic stimulating factors): A. Hemoglobin (HB) ≥ 90 g/l; B. Neutrophil number (ANC) ≥ 1.5 × 109/L； C. Platelet count (PLT) ≥ 100 × 109/L； 2) Biochemical examination shall meet the following standards: A. TBIL was lower than 1.5 upper limit of normal value (ULN); B. ALT and AST were less than 2.5 ulin, but \< 5 uld in liver metastasis; C. The serum creatinine (CR) \< 1.5 ULN or the clearance rate of endogenous creatinine was more than 60ml / min (Cockcroft Gault formula); D. The results of routine urine test showed that uro was less than 2+ or 24 hours urinary protein was less than 1G;
•Men and women of gestational age must agree to take adequate contraceptive measures throughout the study period and within 6 months after the treatment.
•Sign written informed consent, and it is expected to be in good compliance with the research plan.

Exclusion Criteria

•Mixed NSCLC confirmed by histology or cytology, including mixed squamous cell carcinoma and small cell lung cancer;
•Previously received anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CTLA-4 antibody (or any other antibody acting on T cell costimulation or checkpoint pathway) or any VEGF / VEGFR inhibitor;
•Patients with active brain metastases (for patients with stable symptoms of brain metastases after treatment, they can be selected if they remain stable for at least 4 weeks);
•Imaging evidence of tumor cavity, tumor surrounding or invasion of large blood vessels. In addition, the degree of proximity of the tumor to the large vessels should be considered（ The major vessels in the chest include the main pulmonary artery, left pulmonary artery, right pulmonary artery, four pulmonary veins, superior vena cava, inferior vena cava and aorta.
•Immunosuppressive drugs were used within 28 days before the first use of karelizumab, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose of drugs);
•Received systemic treatment of Chinese herbal medicine with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use for controlling pleural effusion) within 28 weeks before the first administration;
•Inoculate live attenuated vaccine within 30 days of the first administration or within the expected period of the study（ For the new coronal vaccine vaccinators, whether they can be selected according to the judgment of the researchers)
•According to the judgment of the researcher, there is uncontrolled pleural effusion, pericardial effusion or ascites, or the patient has received serous cavity effusion drainage for treatment within 4 weeks before treatment.
•Subjects with severe infection within 1 month before enrollment, including but not limited to infection complications, bacteremia, severe pneumonia, etc; Subjects with any active infection, or fever of unknown origin \> 38.5 ℃ occurred during screening or before the first administration;
•Patients with active autoimmune disease or immunodeficiency, or with the above-mentioned history, including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease, hypophysitis, vasculitis, nephritis, etc.) were not included. The following exceptions: Patients with a history of autoimmune hypothyroidism but receiving thyroid hormone replacement therapy were included in the study. After treatment with insulin regimen, patients with type 1 diabetes who have controlled glycemic control can participate in this study.